Zobrazeno 1 - 10
of 63
pro vyhledávání: '"Lestini, Brian"'
Autor:
Rizvi, Naiyer A, Mazières, Julien, Planchard, David, Stinchcombe, Thomas E, Dy, Grace K, Antonia, Scott J, Horn, Leora, Lena, Hervé, Minenza, Elisa, Mennecier, Bertrand, Otterson, Gregory A, Campos, Luis T, Gandara, David R, Levy, Benjamin P, Nair, Suresh G, Zalcman, Gérard, Wolf, Jürgen, Souquet, Pierre-Jean, Baldini, Editta, Cappuzzo, Federico, Chouaid, Christos, Dowlati, Afshin, Sanborn, Rachel, Lopez-Chavez, Ariel, Grohe, Christian, Huber, Rudolf M, Harbison, Christopher T, Baudelet, Christine, Lestini, Brian J, Ramalingam, Suresh S
Publikováno v:
In The Lancet Oncology March 2015 16(3):257-265
Autor:
Kreiger, Portia A, Judkins, Alexander R, Russo, Pierre A, Biegel, Jaclyn A, Lestini, Brian J, Assanasen, Chatchawin, Pawel, Bruce R
Publikováno v:
In Modern Pathology January 2009 22(1):142-150
Autor:
Lestini, Brian J, Sagnella, Sharon M, Xu, Zhong, Shive, Matthew S, Richter, Nancy J, Jayaseharan, Johnsamuel, Case, Aubrey J, Kottke-Marchant, Kandice, Anderson, James M, Marchant, Roger E ∗
Publikováno v:
In Journal of Controlled Release 2002 78(1):235-247
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Baseline patient characteristics from CA209-003 in all treated patients. (DOCX 17Â kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c02d81f2502497286eee3d81d2bf4be
Study design. AE = adverse event; cCR = confirmed complete response; cPD = confirmed progressive disease; CR = complete response; PD = progressive disease; PR = partial response; SD = stable disease; uCR = unconfirmed complete response; Q2W = every 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e445446be8a7666cc6be481cd9db079
Actual dose received versus dosing day. MEL = melanoma; NSCLC = non-small cell lung cancer; RCC = renal cell carcinoma. (PDF 933 kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87a91b2756f3a575074ecbb402c26ae8
Exposure-response for efficacy of nivolumab by dose level in RCC. (A) Probability of OR vs Cminss, overall and by dose. (B) Probability of OR vs CL, overall and by dose. CL = clearance; Cminss = steady-state trough concentration; OR = objective respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68aaad11a06115417ff05b1b827a35fc
Exposure-response for efficacy of nivolumab by dose level in NSCLC. (A) Probability of OR vs Cminss, overall and by dose. (B) Probability of OR vs CL, overall and by dose. CL = clearance; Cminss = steady-state trough concentration; NSCLC = non-small
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70baa4976f5f43bb01b2668db7606d51
Dose information summary across all tumor types. (DOCX 16Â kb)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c5a4b80190f822818a4946edb89b640